NO20040933L - Nye gamma-sekretaseinhibitorer. - Google Patents
Nye gamma-sekretaseinhibitorer.Info
- Publication number
- NO20040933L NO20040933L NO20040933A NO20040933A NO20040933L NO 20040933 L NO20040933 L NO 20040933L NO 20040933 A NO20040933 A NO 20040933A NO 20040933 A NO20040933 A NO 20040933A NO 20040933 L NO20040933 L NO 20040933L
- Authority
- NO
- Norway
- Prior art keywords
- secretase inhibitors
- novel gamma
- gamma
- novel
- secretase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31001301P | 2001-08-03 | 2001-08-03 | |
| US35551002P | 2002-02-06 | 2002-02-06 | |
| PCT/US2002/024323 WO2003014075A2 (en) | 2001-08-03 | 2002-08-01 | Novel gamma secretase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20040933L true NO20040933L (no) | 2004-03-03 |
Family
ID=26977148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20040933A NO20040933L (no) | 2001-08-03 | 2004-03-03 | Nye gamma-sekretaseinhibitorer. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6683091B2 (no) |
| EP (1) | EP1492765B1 (no) |
| JP (1) | JP4418671B2 (no) |
| KR (1) | KR20040019094A (no) |
| CN (1) | CN1304390C (no) |
| AR (1) | AR034390A1 (no) |
| AT (1) | ATE515495T1 (no) |
| AU (1) | AU2002324582B9 (no) |
| BR (1) | BR0211698A (no) |
| CA (1) | CA2455863C (no) |
| CO (1) | CO5550419A2 (no) |
| HU (1) | HUP0600673A3 (no) |
| IL (1) | IL159848A0 (no) |
| MX (1) | MXPA04001014A (no) |
| NO (1) | NO20040933L (no) |
| PL (1) | PL372212A1 (no) |
| RU (1) | RU2004106540A (no) |
| TW (1) | TWI242555B (no) |
| WO (1) | WO2003014075A2 (no) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| WO2003032994A2 (de) * | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
| WO2003055850A1 (fr) | 2001-12-27 | 2003-07-10 | Daiichi Pharmaceutical Co., Ltd. | Inhibiteurs de la production/secretion de la proteine amyloide-$g(b) |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| MXPA05013631A (es) | 2003-06-30 | 2006-02-24 | Daiichi Seiyaku Co | Derivado heterociclico de metilsulfona. |
| MXPA06001558A (es) * | 2003-08-08 | 2006-05-15 | Schering Corp | Inhibidores de amina ciclica bace-1 que poseen un sustituyente heterociclico. |
| MXPA06001559A (es) | 2003-08-08 | 2006-05-15 | Schering Corp | Inhibidores de amina ciclica bace-1 que poseen una benzamida como sustituyente. |
| EP2369014A1 (en) | 2004-02-03 | 2011-09-28 | The Regents Of The University Of Michigan Office Of Technology Transfer | Compositions and methods for characterizing, regulating, diagnosing and treating cancer |
| CA2554779A1 (en) * | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| EP1740570A2 (en) * | 2004-04-05 | 2007-01-10 | Schering Corporation | Novel gamma secretase inhibitors |
| EP1758884A2 (en) * | 2004-05-20 | 2007-03-07 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| AR050994A1 (es) * | 2004-06-30 | 2006-12-13 | Schering Corp | N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas, y composicion farmaceutica en base al compuesto |
| JP2008507538A (ja) * | 2004-07-22 | 2008-03-13 | シェーリング コーポレイション | 置換アミドβセクレターゼインヒビター |
| US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
| AR056865A1 (es) | 2005-06-14 | 2007-10-31 | Schering Corp | Heterociclos nitrogenados y su uso como inhibidores de proteasas, composiciones farmaceuticas |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| EP1945754B1 (en) | 2005-10-31 | 2014-07-23 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| PT2500360E (pt) | 2005-10-31 | 2015-10-15 | Oncomed Pharm Inc | Composições e métodos para diagnóstico e tratamento do cancro |
| RU2448964C2 (ru) | 2006-01-20 | 2012-04-27 | Шеринг Корпорейшн | КАРБОЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ АРИЛСУЛЬФОНЫ, ИХ ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ОБЛАДАЮЩАЯ СВОЙСТВАМИ ИНГИБИТОРА γ-СЕКРЕТАЗЫ |
| EP1998785A4 (en) * | 2006-02-21 | 2009-06-17 | Univ Michigan | CANCER TREATMENT USING A HEDGEHOG SIGNALING PATH |
| US8133857B2 (en) * | 2006-03-07 | 2012-03-13 | The Brigham and Women's FHospital, Inc. | NOTCH inhibition in the treatment of atherosclerosis |
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
| TW200813054A (en) * | 2006-06-02 | 2008-03-16 | Elan Pharm Inc | Fused, tricyclic sulfonamide inhibitors of gamma secretase |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| US8148147B2 (en) | 2007-01-24 | 2012-04-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
| ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| RU2483061C2 (ru) | 2007-07-05 | 2013-05-27 | Шеринг Корпорейшн | Тетрагидропиранохроменовые ингибиторы гамма-секретазы |
| CN101970445A (zh) | 2007-07-17 | 2011-02-09 | 先灵公司 | 苯磺酰基-色满、硫代色满、四氢萘和相关γ分泌酶抑制剂 |
| SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| WO2010054078A1 (en) * | 2008-11-06 | 2010-05-14 | Schering Corporation | Gamma secretase modulators |
| WO2010138901A1 (en) * | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
| US20120129189A1 (en) * | 2009-07-17 | 2012-05-24 | Chulan Kwon | Methods of Controlling Cell Proliferation |
| US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| EP2485920B1 (en) | 2009-10-08 | 2016-04-27 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| US8557826B2 (en) | 2009-10-08 | 2013-10-15 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use |
| US8563543B2 (en) | 2009-10-08 | 2013-10-22 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| KR101790806B1 (ko) | 2010-03-10 | 2017-11-20 | 프로비오드룩 아게 | 글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제 |
| JP2013530929A (ja) | 2010-04-01 | 2013-08-01 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ｆｒｉｚｚｌｅｄ結合剤およびその使用 |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| JP5275315B2 (ja) * | 2010-10-01 | 2013-08-28 | 学校法人近畿大学 | 新規化合物及びβ−セクレターゼ阻害剤 |
| EP2638014B1 (en) | 2010-11-08 | 2017-01-04 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| WO2012138590A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| MX2014002113A (es) | 2011-08-22 | 2014-04-25 | Merck Sharp & Dohme | Iminotiazinas sustituidas en 2-espiro y sus mono y bioxidos como inhibidores de enzima de disociacion de proteina precursora amiloide del sitio beta, composiciones, y su uso. |
| US9629891B2 (en) | 2011-10-17 | 2017-04-25 | Nationwide Children's Hospital, Inc. | Products and methods for aortic abdominal aneurysm |
| CA2871514C (en) | 2012-05-08 | 2020-08-25 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of ror.gamma.activity and the treatment of disease |
| EP2847198B1 (en) | 2012-05-08 | 2016-12-14 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease |
| CA2887711A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
| US9359444B2 (en) | 2013-02-04 | 2016-06-07 | Oncomed Pharmaceuticals Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
| WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| AU2015222917A1 (en) | 2014-02-27 | 2016-09-15 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
| EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
| AU2015256190B2 (en) | 2014-05-05 | 2019-08-15 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| CN104027810B (zh) * | 2014-06-30 | 2016-02-10 | 王涛 | 一种构建先天性肝内胆管发育不良综合征动物模型的方法 |
| US10221142B2 (en) | 2015-02-11 | 2019-03-05 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof |
| AU2016257997A1 (en) | 2015-05-05 | 2017-11-09 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| CN107980042B (zh) | 2015-06-11 | 2021-10-08 | 莱斯拉公司 | 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物 |
| MX2018005004A (es) | 2015-10-27 | 2018-09-12 | Merck Sharp & Dohme | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. |
| EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
| US20210290633A1 (en) | 2018-07-19 | 2021-09-23 | INSERM (Insstitut National de la Santé et de la Recherche Médicale) | Combination for treating cancer |
| EP4244391A1 (en) | 2020-11-16 | 2023-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1328176A (fr) * | 1962-07-06 | 1963-05-24 | Monsanto Chemicals | Procédé de préparation de dérivés des hydroquinoléines |
| JPS556321A (en) * | 1978-06-27 | 1980-01-17 | Konishiroku Photo Ind Co Ltd | Color photographic material |
| JPS6395447A (ja) * | 1986-10-11 | 1988-04-26 | Konica Corp | 色素画像の光堅牢性が改良されたハロゲン化銀写真感光材料 |
| NZ509439A (en) * | 1998-07-30 | 2002-10-25 | Warner Lambert Co | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| CN1348442A (zh) | 1999-02-26 | 2002-05-08 | 默克公司 | 新的磺胺化合物及其应用 |
| IL138686A0 (en) * | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
| CA2387493A1 (en) * | 1999-10-08 | 2001-04-19 | Lorin Andrew Thompson | Amino lactam sulfonamides as inhibitors of a.beta. protein production |
-
2002
- 2002-08-01 HU HU0600673A patent/HUP0600673A3/hu unknown
- 2002-08-01 IL IL15984802A patent/IL159848A0/xx unknown
- 2002-08-01 CN CNB028152603A patent/CN1304390C/zh not_active Expired - Fee Related
- 2002-08-01 RU RU2004106540/04A patent/RU2004106540A/ru not_active Application Discontinuation
- 2002-08-01 BR BR0211698-7A patent/BR0211698A/pt not_active IP Right Cessation
- 2002-08-01 WO PCT/US2002/024323 patent/WO2003014075A2/en active IP Right Grant
- 2002-08-01 CA CA2455863A patent/CA2455863C/en not_active Expired - Fee Related
- 2002-08-01 PL PL02372212A patent/PL372212A1/xx unknown
- 2002-08-01 US US10/210,829 patent/US6683091B2/en not_active Expired - Fee Related
- 2002-08-01 MX MXPA04001014A patent/MXPA04001014A/es active IP Right Grant
- 2002-08-01 EP EP02759233A patent/EP1492765B1/en not_active Expired - Lifetime
- 2002-08-01 KR KR10-2004-7001505A patent/KR20040019094A/ko not_active Application Discontinuation
- 2002-08-01 AU AU2002324582A patent/AU2002324582B9/en not_active Ceased
- 2002-08-01 JP JP2003519025A patent/JP4418671B2/ja not_active Expired - Fee Related
- 2002-08-01 TW TW091117313A patent/TWI242555B/zh active
- 2002-08-01 AT AT02759233T patent/ATE515495T1/de not_active IP Right Cessation
- 2002-08-01 AR ARP020102926A patent/AR034390A1/es unknown
-
2004
- 2004-01-21 CO CO04003799A patent/CO5550419A2/es not_active Application Discontinuation
- 2004-03-03 NO NO20040933A patent/NO20040933L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US6683091B2 (en) | 2004-01-27 |
| TWI242555B (en) | 2005-11-01 |
| CN1630651A (zh) | 2005-06-22 |
| BR0211698A (pt) | 2004-11-09 |
| KR20040019094A (ko) | 2004-03-04 |
| MXPA04001014A (es) | 2004-05-27 |
| WO2003014075A2 (en) | 2003-02-20 |
| EP1492765A2 (en) | 2005-01-05 |
| HUP0600673A2 (en) | 2006-12-28 |
| JP4418671B2 (ja) | 2010-02-17 |
| ATE515495T1 (de) | 2011-07-15 |
| CA2455863C (en) | 2010-10-12 |
| CN1304390C (zh) | 2007-03-14 |
| JP2005504760A (ja) | 2005-02-17 |
| IL159848A0 (en) | 2004-06-20 |
| AU2002324582B2 (en) | 2006-01-05 |
| CA2455863A1 (en) | 2003-02-20 |
| AU2002324582B9 (en) | 2006-02-16 |
| CO5550419A2 (es) | 2005-08-31 |
| PL372212A1 (en) | 2005-07-11 |
| AR034390A1 (es) | 2004-02-25 |
| HUP0600673A3 (en) | 2011-08-29 |
| RU2004106540A (ru) | 2005-07-27 |
| WO2003014075A3 (en) | 2004-09-30 |
| US20030135044A1 (en) | 2003-07-17 |
| EP1492765B1 (en) | 2011-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20040933L (no) | Nye gamma-sekretaseinhibitorer. | |
| NO20034308L (no) | Nye tyrokinase-inhibitorer | |
| NO20035428D0 (no) | Nye anti-ineffektiver | |
| NO20034992D0 (no) | Nye 4-aninlinokinolin-3-karboksamider | |
| ATE308544T1 (de) | N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren | |
| NO20040014L (no) | Nye forbindelser | |
| NO20041003L (no) | Nye forbindelser | |
| NO20034665D0 (no) | Nye forbindelser | |
| DE60234125D1 (de) | E inhibitoren | |
| NO20044588L (no) | Nye forbindelser | |
| NO20044432L (no) | Nye forbindelser | |
| NO20053248D0 (no) | Kerosenblanding. | |
| ATE304015T1 (de) | Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren | |
| NO20043696L (no) | Gamma-sekretaseinhibitorer | |
| NO20034970D0 (no) | Nye arylheteroalkylaminderivater | |
| NO20052248D0 (no) | Svivelstykkesystem. | |
| NO20034695D0 (no) | Nye sammensetninger | |
| NO20051500D0 (no) | Substituerte heterocyklylpyrimidiner. | |
| NO20041185L (no) | Nye sykloheksylsulfoner | |
| NO20051497D0 (no) | Beta-laktamaseinhibitorprodrug. | |
| NO20030274D0 (no) | Nye aryleten-sulfonamider | |
| NO20035248D0 (no) | Nye fenylalkyloksy-fenyl derivater | |
| ITMI20032170A1 (it) | Tagliacimosse. | |
| NO20025902D0 (no) | Nye fenylpiperaziner | |
| NO20044098L (no) | Nye forbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |